Live Breaking News & Updates on Immunology Innovation

Stay updated with breaking news from Immunology innovation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

argenx Reports Half Year 2022 Financial Results and

$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on. ....

United States , Clayton Smith , Tim Van Hauwermeiren , Camilla Sylvest , University Of Colorado Anschutz Medical Campus , Zai Lab , European Commission , Oncoverity Inc , Corporate Affairs At Novo Nordisk , China National Medical Products Administration , Efgartigimod Research , University Of Colorado , European Medicines Agency , Committee For Medicinal Products Human Use , Immunology Innovation Program , License Application , National Medical Products Administration , Chief Executive Officer , Medicinal Products , Human Use , Clinical Trial Application , Colorado Anschutz Medical Campus , Immunology Innovation , Executive Vice President , Commercial Strategy , Corporate Affairs ,

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022 Biologics License Application ....

United States , United Kingdom , Clayton Smith , Kelsey Kirk , Beth Delgiacco , Tim Van Hauwermeiren , Camilla Sylvest , Zai Lab , Oncoverity Inc , Japaneuropean Commission , China National Medical Products Administration , Committee For Medicinal Products Human Use , Immunology Innovation Program , University Of Colorado Anschutz Medical Campus , Drug Administration , European Commission , Corporate Affairs At Novo Nordisk , Exchange Commission , Efgartigimod Research , University Of Colorado , European Medicines Agency , Devices Agency , License Application , National Medical Products Administration , Chief Executive Officer , Medicinal Products ,

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , United Kingdom , Bruxelles Capitale , Kelsey Kirk , Michelle Greenblatt , Beth Delgiacco , Tim Van Hauwermeiren , International Congress On Neuromuscular Diseases , European Medicines Agency On Marketing Authorization Application , European Academy Of Neurology , Zai Lab , Drug Administration , Society For Investigative Dermatology Annual Meeting , Efgartigimod Research , National Health Insurance , Meeting Of The Japanese Society Neurology , Immunology Innovation Program , Chief Executive Officer , European Medicines Agency , Marketing Authorization Application , License Application , Clinical Trial Application , Myasthenia Gravis Foundation , America International Conference , Related Disorders , Investigative Dermatology Annual Meeting ,

argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , United Kingdom , Kelsey Kirk , Michelle Greenblatt , Beth Delgiacco , Yvonne Greenstreet , Van Hauwermeiren , Tim Van Hauwermeiren , Malini Moorthy , International Financial Reporting Standards , European Medicines Agency On Marketing Authorization Application , Zai Lab , Japan Ministry Of Health , Bayer Healthcare Pharmaceuticals , Health Canada , Immunology Innovation Program , International Accounting Standards Board , General Counsel , Chief Executive Officer , European Medicines Agency , Marketing Authorization Application , Clinical Trial Application , Greater China , Agomab Therapeutics , Immunology Innovation , Globe Newswire ,

argenx Highlights Strategic Priorities for 2022

Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications ....

United States , Kelsey Kirk , Michelle Greenblatt , Beth Delgiacco , Van Hauwermeiren , Tim Van Hauwermeiren , Zai Lab , Drug Administration , Exchange Commission , European Medicines Agency , Devices Agency Of Marketing Authorization Application , Health Canada , Immunology Innovation Program , Japan Pharmaceuticals , Euronext Nasdaq , Chief Executive Officer , Medical Devices Agency , Marketing Authorization Application , Greater China , Clinical Trial Application , Immunology Innovation , Healthcare Conference Presentation , Healthcare Conference ,